Complete Response in Metastatic Rectal Cancer with Hepatic and Pulmonary Metastases Treated with Second-Line FOLFIRI plus Ramucirumab: A Case Report - PubMed
4 hours ago
- #Ramucirumab
- #Complete Response
- #Metastatic Colorectal Cancer
- A 61-year-old woman with stage IVB rectal cancer (KRAS/BRAF wild-type, microsatellite stable, HER2-negative) achieved a complete radiological response after second-line treatment with FOLFIRI plus ramucirumab.
- First-line therapy with FOLFOX plus panitumumab showed regression in rectal and liver lesions, but one pulmonary nodule progressed, prompting the switch to second-line treatment.
- Following second-line therapy, a biopsy of the rectal scar confirmed no malignancy, and a watch-and-wait strategy was adopted to prioritize organ preservation.
- The patient received consolidation chemotherapy and remained recurrence-free for 6 months after achieving complete response.
- This case highlights the potential of second-line FOLFIRI plus ramucirumab to achieve complete response in metastatic colorectal cancer, even after progression on anti-EGFR therapy.